BioVie reports biomarker-defined subgroups with different responses in Phase 2 Long COVID trial
BioVie Inc. presented new biomarker analyses from its Phase 2 ADDRESS‑LC trial, showing two distinct patient endotypes. The high‑inflammatory group showed notable gains in objective cognition, while the low‑white‑blood‑cell/low‑myeloid group improved in fatigue and post‑exertional malaise. The overall study of 203 participants did not achieve statistical significance on the primary endpoints. BioVie will share additional data at the upcoming Long COVID International Conference in Nice.
Why it matters
The company’s identification of response‑specific subgroups could guide future trial designs and target enrollment, potentially affecting the valuation of its investigational drug bezisterim. Investors should watch for follow‑up data that may influence expectations for regulatory approval or partnership opportunities.
Key facts
- 1The ADDRESS‑LC trial enrolled 203 participants who received either 20 mg of bezisterim twice daily or a matching placebo for 12 weeks. finance.yahoo.com
- 2In the high‑inflammatory endotype (67 participants), bezisterim produced a large treatment effect on objective cognition (Cohen’s d ≈ 0.83, p = 0.001). rttnews.com
- 3In the low‑WBC/low‑myeloid endotype (44 participants), the drug improved fatigue and post‑exertional malaise (Cohen’s d ≈ 0.80‑0.90, p ≈ 0.11). rttnews.com
- 4Neuropeptide Y levels fell about 33% relative to placebo at Week 12. finance.yahoo.com
- 5Treatment‑emergent adverse events occurred in 41.6% of bezisterim‑treated participants versus 55.9% on placebo; no deaths or serious events were reported. finance.yahoo.com
- 6The stock was trading at $1.32, down 0.75% after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.